Latest Clinical research Stories
Majority of biopharma executives believe Strategic Partnerships positively impact their engagement with CROs BOSTON, April 22, 2013 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22(nd) Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic...
PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA The agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program. The initial development will be performed at DSM Biologics'...
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in June 2013. PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing...
-This is the first study that studies and quantifies 1,600 known adverse effects of drugs currently on the market. -The scientists Miquel Duran and Patrick Aloy provide a description of the molecular processes responsible for more than 1,000 secondary effects. -This knowledge, which is available to the scientific community, may be of great use to minimize and predict adverse effects during drug design. Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory...
SAN DIEGO, April 19, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. The trial did not demonstrate statistically significant efficacy on the primary endpoint (UPDRS-motor off). However, one of the "key secondary endpoints" (Diary-off score), as defined and...
FALLS CHURCH, Va., April 19, 2013 /PRNewswire-iReach/ -- Tenth Annual Medical Device Quality CongressFrom Risk Management to Postmarket Surveillance **Presented by FDAnews**June 4-6, 2013 -- Bethesda, MD www.fdanews.com/MDQC2013 (Photo: http://photos.prnewswire.com/prnh/20130419/CG97972) FDAnews has put together a world-class group of experts who will educate attendees of the 10th Annual Medical Device Quality Congress and provide them with the tools and strategies they need to go...
DUBLIN, April 19, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "The Politics of Pharma: Washington, States, and the Court's Impact on the Industry [http://www.researchandmarkets.com/research/x8fq2f/the_politics_of ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma...
SANTIAGO, Chile, April 18, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Company will be conducting a meeting with clinical investigators in Santiago, Chile, on April 18th, 2013. The meeting will include presentations about the upcoming Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of...
Discussion Focuses on Key Market Access Issues Affecting the Success of Biologics and Biosimilars BURLINGTON, Mass., April 18, 2013 /PRNewswire/ -- Decision Resources Group is pleased to announce a distinguished lineup of speakers who will be joining its well-regarded Competitive Landscape Seminar Series focusing on Biologics and Biosimilars on May 2, 2013 at the Hotel Solamar in San Diego, CA. The panel discussion will focus on the key issues affecting the success of the...
Imprimis Pharmaceuticals, Inc., Concluded its April 15th, 2013 Meeting with the FDA in Washington, D.C., and Reviewed the Company's Development Program for its Lead Phase III Drug Candidate, Impracor(TM) SOLANA BEACH, Calif., April 18, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced that on April 15(th), 2013, the Company attended its Type C meeting with the U.S. Food and Drug Administration (FDA) which included the review of the development plan for...
